New heart mapping tech could improve AFib treatment safety

NCT ID NCT07421076

Recruiting now Disease control Sponsor: Abbott Medical Devices Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study tests a new mapping catheter and software to help doctors treat atrial fibrillation, a common heart rhythm problem. About 200 Chinese patients will receive a standard ablation procedure, but doctors will use the new tools to guide them. The goal is to see if the new devices are safe and effective at identifying problem areas in the heart.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Grid X Mapping Catheter and EnSite X Software (device)
What this could lead to: If successful, this could provide a safer and more effective way to map and treat atrial fibrillation, potentially improving outcomes for patients.
What could go wrong: This is an early-stage study with only 200 participants, so results may not apply to everyone. There are risks like heart damage or stroke from the procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAROXYSMAL ATRIAL FIBRILLATION (PAF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation paroxysmal atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PAROXYSMAL ATRIAL FIBRILLATION (PAF)

Contacts and locations

Locations

Beijing Anzhen Hospital, Capital Medical University
RECRUITING

Beijing, China
Qilu Hospital of Shandong University
RECRUITING

Jinan, Shandong, China
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, China
The First Affiliated Hospital of Ningbo University
RECRUITING

Ningbo, Zhejiang, China
West China Hospital of Sichuan University
RECRUITING

Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.